Vitrivax Announces $87 Million Series C Financing for Lyme Vaccine Candidate
Vitrivax announced a $87 million Series C financing to advance its Lyme disease vaccine candidate.
Vitrivax announced a $87 million Series C financing to advance its Lyme disease vaccine candidate.